Multiple Myeloma in Relapse Not Yet Recruiting Phase 2 Trials for Selinexor (DB11942)

IndicationStatusPhase
DBCOND0036092 (Multiple Myeloma in Relapse)Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03944057A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple MyelomaTreatment